← Back to screener

SELLAS Life Sciences Group, Inc. SLS

Rank #1268 · Nasdaq · $1.8B market cap
⚠ Going-concern flag — the auditor (Baker Tilly US, LLP) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.
Score
50.9
P/E
-58.3
P/B
-225.78
ROE
387.2%
Op. Margin
–%
Debt Ratio
-125%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -58.3x, P/B -225.78x. Ranks in the top 84% of the universe.

Profitability ★★★★★
Excellent

ROE 387.2%. Ranks in the top 1% of the universe.

Safety ★★★★★
Excellent

Debt ratio -125%. Ranks in the top 6% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Profitability is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011––$-0.0B$0.0B–208
2012––$-0.0B$0.0B–206
2013–$-0.0B$-0.0B$0.0B–98
2014–$-0.0B$-0.0B$0.0B–1395
2015–$-0.0B$-0.1B$0.0B–117
2016–$-0.0B$-0.0B$0.0B–508
2017–$-0.0B$-0.0B$-0.0B–-93
2018––$-0.0B$0.0B–1520
2019––$-0.0B$0.0B–222
2020$0.0B$-0.0B$-0.0B$0.0B–200
2021$0.0B$-0.0B$-0.0B$0.0B-893.8297
2022$0.0B$-0.0B$-0.0B$0.0B-332.821
2023$0.0B$-0.0B$-0.0B$0.0B-4195.079
2024–$-0.0B$-0.0B$0.0B–293
2025–$-0.0B$-0.0B$-0.0B–-125

← See the full screener